Search results
Results From The WOW.Com Content Network
Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50 years of age. Thyroglobulin (Tg) can be used as a tumor marker for well-differentiated follicular thyroid cancer. Thyroid follicular cells are the thyroid cells responsible for the production and secretion of thyroid hormones.
Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma , [ 1 ] or it can be a malignant neoplasm ( thyroid cancer ), such as papillary , follicular , medullary or anaplastic thyroid cancer . [ 2 ]
A follicular variant of papillary thyroid cancer also exists. [36] Newly reclassified variant: noninvasive follicular thyroid neoplasm with papillary-like nuclear features is considered an indolent tumor of limited biologic potential. Follicular thyroid cancer (10 to 20% of cases [35]) – occasionally seen in people with Cowden syndrome.
Histopathology of NIFTP, H&E stain. [1]Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor that was previously classified as an encapsulated follicular variant of papillary thyroid carcinoma, [2] necessitating a new classification as it was recognized that encapsulated tumors without invasion have an indolent behavior, [2] and may ...
In situ lymphoid neoplasia (ISLN, also termed in situ lymphoma) is a precancerous condition newly classified by the World Health Organization in 2016. The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). [1]
Proliferating trichilemmal cysts (also known as a pilar tumor, proliferating follicular cystic neoplasm, proliferating pilar tumor, and proliferating trichilemmal tumor) [1] is a cutaneous condition, characterized by proliferations of squamous cells forming scroll-like structures.
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
These findings are similar to those in follicular lymphoma but the malignant cells in DFL generally have fewer genomic abnormalities than those in follicular lymphoma and the profile of overexpressed genes in DFL tissues more closely resemble those in marginal zone than follicular lymphoma tissues. The diagnosis of DFL depends on finding: the ...